Jamaica’s ‘Good Ganja Sense’ Campaign Aims to Correct Misconceptions About Cannabis
by Bethan Rose
The news, which was officially announced in a letter, confirmed that the bank would no longer be granting new acquisitions or “short” positions in cannabis-focused businesses. However, the letter also noted that clients who already maintain such positions will be able to liquidate them.
“J.P. Morgan (JPMS) has introduced a framework that is designed to comply with U.S. money laundering laws and regulations by restricting certain activities in the securities of U.S. Marijuana Related Businesses,” reads an excerpt from the bank’s letter, which was addressed for the attention of its clients.
The bank’s decision comes hot off the heels of Credit Suisse’s $5.5 billion loss from the crash of the Archegos Capital Management investment fund. Numerous banks were left dealing with losses as a direct effect of this unexpected disaster. Since this time, wealth management firms have been forced to figure out exactly how much they’re willing to risk.
Although a swelling number of U.S. states have legalized cannabis for medical and/or recreational purposes, federal law still deems the plant to be an illicit substance. Consequently, banks that choose to collaborate with cannabis-focused businesses face the risk of being penalized for their actions.
Only specific cannabis-related businesses can list on the NASDAQ and NYSE, such as Canadian companies that do not carry out retail activities in the states. Conversely, companies that deal directly with cannabis cultivation or cannabis sales cannot list on the aforementioned stock exchanges.
Any U.S.-operating company that has a “direct nexus to cannabis-related activities” and does not list shares on the following stock exchanges must also abide by the restrictions:
Nonetheless, many companies are skirting around the rules to continue trading on over-the-counter exchanges.
A recent report published by MarketWatch confirmed that most cannabis company investors have been “burned by stock market losses” in 2021. Despite a poor performance this year, the sector is continuously growing as more U.S. states introduce legal adult-use markets. As of December 2021, a total of 18 U.S. states, Guam, and the District of Columbia have legalized cannabis for recreational use and sale.
Mainly, cannabis multi-state operators (MSOs) like Curaleaf Holdings (OTC:CURLF) and Trulieve Cannabis (OTC:TCNNF) will feel the effects of the financial institution’s decision. Why? Because cannabis’ federally illegal status in the U.S. means that such companies have no choice but to engage in OTC trading activities.
In addition to this, it’s likely that panic-selling from concerned investors could cause the cannabis stock market to struggle further now that JPMorgan Chase will stop offering new acquisitions or “short” positions in cannabis-focused businesses. Plus, the U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) issued a warning about delta-8 THC products back in September—something that is likely to put a strain on the cannabis sector moving forwards.
JPMorgan Chase & Co. identifies as an American multinational investment bank. The financial services holding company is headquartered in New York City and was incorporated in Delaware. J.P. Morgan’s roots extend as far back as 1799, though the conversion of J.P. Morgan and Chase into JPMorgan Chase happened in 2000. Currently, the bank serves a broad scope of individuals and corporations in over 100 different countries.
Some of the world-renowned financial institution’s heritage firms include:
Globally recognized for having top-rated finance technology and mobile banking services, JPMS prides itself on restructuring businesses to enhance their profitability and market permanence, not to mention the level of control maintained over the companies it collaborates with.
Aside from JPMS, another American bank that has been actively operating in the realm of cannabis trading is Cowen and Co. Back in September, the financial institution sent a letter to its clients outlining how it had decided to boost cash margin provisions for cannabis-associated trades on its platform.
The flowering buds of the cannabis plant have always been the star of the show due to their high concentration of cannabinoids like THC and CBD that create effects for consumers. But what many don’t know is that other parts of the plant—specifically the trim removed after harvesting—can be used for a variety of purposes….
Many states across the U.S. have legalized cannabis for medical and retail consumption. The regulations governing these industries primarily focus on the products’ content of the two most prominent cannabinoids found in the cannabis plant, cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). But in recent months, a new cannabinoid known as delta-8-tetrahydrocannabinol (delta-8 THC) has entered the…
Humans were experimenting with cannabis use for medical and recreational purposes before we traveled the Silk Road or even wrote history down (1). Archeologists discovered pounds of dried cannabis in ancient Chinese shaman bags, and cannabis was burned as an incense offering at the Holy of Holies altar in a Judahite shrine in Tel Arad,…
The word ‘endocannabinoid’ seems to belong to cannabis at first glance. However, some may be surprised to find out that all humans have an endocannabinoid system and professionals are still trying to completely understand the endocannabinoid system (ECS). Researchers have discovered the ECS by trying to understand how cannabinoids play a role in the body….
A team of Oregon State University-affiliated researchers has uncovered an unlikely tool in the fight against COVID-19. Their study, published in the Journal of Nature Products on Jan. 10, found that cannabis compounds can prevent the COVID-19 virus from penetrating healthy human cells. Specifically, the team identified the cannabinoid acids cannabigerolic acid (CBGA) and cannabidiolic…
Louisiana’s medical cannabis expansion has gotten mixed reviews, Mississippi’s proposed legalization legislation may be too good to be true, and Colorado cemented…
A new report carried out by drug policy reform organization Volteface suggests that the United Kingdom could be leaving £1.2 billion on…